These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34809510)

  • 21. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
    Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
    Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deucravacitinib for the Treatment of Psoriatic Disease.
    Lé AM; Puig L; Torres T
    Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
    Papp K; Gordon K; Thaçi D; Morita A; Gooderham M; Foley P; Girgis IG; Kundu S; Banerjee S
    N Engl J Med; 2018 Oct; 379(14):1313-1321. PubMed ID: 30205746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
    Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
    Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deucravacitinib in the treatment of psoriasis.
    Estevinho T; Lé AM; Torres T
    J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.
    Du SS; Fang YQ; Zhang W; Rao GW
    Curr Med Chem; 2024; 31(20):2900-2920. PubMed ID: 38904160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
    Martin G
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
    Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
    Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
    Liu C; Lin J; Langevine C; Smith D; Li J; Tokarski JS; Khan J; Ruzanov M; Strnad J; Zupa-Fernandez A; Cheng L; Gillooly KM; Shuster D; Zhang Y; Thankappan A; McIntyre KW; Chaudhry C; Elzinga PA; Chiney M; Chimalakonda A; Lombardo LJ; Macor JE; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2021 Jan; 64(1):677-694. PubMed ID: 33370104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
    Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
    J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
    Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
    Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.
    Leit S; Greenwood J; Carriero S; Mondal S; Abel R; Ashwell M; Blanchette H; Boyles NA; Cartwright M; Collis A; Feng S; Ghanakota P; Harriman GC; Hosagrahara V; Kaila N; Kapeller R; Rafi SB; Romero DL; Tarantino PM; Timaniya J; Toms AV; Wester RT; Westlin W; Srivastava B; Miao W; Tummino P; McElwee JJ; Edmondson SD; Masse CE
    J Med Chem; 2023 Aug; 66(15):10473-10496. PubMed ID: 37427891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
    Chang Y; Xu S; Ding K
    J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor.
    Menet CJ
    J Med Chem; 2018 Oct; 61(19):8594-8596. PubMed ID: 30252456
    [No Abstract]   [Full Text] [Related]  

  • 36. The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells.
    Enerbäck C; Sandin C; Lambert S; Zawistowski M; Stuart PE; Verma D; Tsoi LC; Nair RP; Johnston A; Elder JT
    Sci Rep; 2018 May; 8(1):7043. PubMed ID: 29728633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
    Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature.
    Potestio L; Ruggiero A; Fabbrocini G; Martora F; Megna M
    Psoriasis (Auckl); 2023; 13():19-26. PubMed ID: 37168605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.